Number of the records: 1  

The Potential Role of CD133 in Immune Surveillance and Apoptosis: A Mitochondrial Connection?

  1. 1.
    SYSNO ASEP0369486
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleThe Potential Role of CD133 in Immune Surveillance and Apoptosis: A Mitochondrial Connection?
    Author(s) Zobalová, Renata (BTO-N) RID
    Prokopová, Kateřina (BTO-N) ORCID
    Stantic, M. (US)
    Stapelberg, M. (US)
    Dong, L.-F. (US)
    Ralph, S.J. (US)
    Akporiaye, E. (US)
    Neužil, Jiří (BTO-N) RID
    Source TitleAntioxidants & Redox Signaling. - : Mary Ann Liebert - ISSN 1523-0864
    Roč. 15, č. 12 (2011), s. 2989-3002
    Number of pages13
    Languageeng - English
    CountryUS - United States
    KeywordsCancer stem-like cells ; protein CD133 ; apoptosis
    Subject RIVEB - Genetics ; Molecular Biology
    R&D ProjectsGA204/08/0811 GA ČR - Czech Science Foundation (CSF)
    GA305/07/1008 GA ČR - Czech Science Foundation (CSF)
    CEZAV0Z50520701 - BTO-N (2007-2013)
    UT WOS000296588900006
    DOI10.1089/ars.2010.3785
    AnnotationRecent research has shown that tumors contain a small subpopulation of stem-like cells that are more resistant to therapy and that are likely to produce second-line tumors. Cancer stem-like cells (CSCs) have been characterized by a variety of markers, including the plasma membrane protein CD133, which is also indicative of the increase of stemness of cultured cancer cells growing as spheres. While the function of this protein has not yet been clearly defined, it may have a role in the stem-like phenotype of CSCs that cause (re-)initiation of tumors as well as their propagation. We hypothesize that CD133 selects for CSC survival against not only immunosurveillance mechanisms but also stress-induced apoptosis. High level of expression of CD133 may be a useful marker of more aggressive tumors that are recalcitrant toward established therapies. Compelling preliminary data indicate that drugs targeting mitochondria may be utilized as a novel, efficient cancer therapeutic modality.
    WorkplaceInstitute of Biotechnology
    ContactMonika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700
    Year of Publishing2012
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.